Jane Street
AVIR icon

Jane Street’s Atea Pharmaceuticals AVIR Stock Holding History

Jane Street’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-177,700
Closed -$855K – 8996
2022
Q4 		$855K Sell
177,700
-8,200
-4% -$41.5K ﹤0.01% 5228
2022
Q3 		$1.06M Buy
185,900
+9,800
+6% +$75K ﹤0.01% 5314
2022
Q2 		$1.25M Buy
176,100
+88,500
+101% +$604K ﹤0.01% 5060
2022
Q1 		$632K Sell
87,600
-137,300
-61% -$932K ﹤0.01% 7039
2021
Q4 		$2.01M Buy
224,900
+206,100
+1,096% +$3.21M ﹤0.01% 4481
2021
Q3 		$659K Sell
18,800
-100
-0.5% -$2.77K ﹤0.01% 6754
2021
Q2 		$406K Buy
+18,900
New +$568K ﹤0.01% 7631

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street's AVIR Position: Q2 2026 in Review

Jane Street sold out of Atea Pharmaceuticals (AVIR) in Q2 2026, closing a stake of 418,296 shares — an estimated $2.25M sold.

Jane Street first reported a position in AVIR in Q2 2021 and held it in 20 quarters. The position peaked at $2.61M in Q3 2021. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Jane Street reported no remaining Atea Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 418,296 Atea Pharmaceuticals shares in Q2 2026, an estimated $2.25M.
  • Jane Street first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 20 quarters.
  • Jane Street's Atea Pharmaceuticals position peaked at $2.61M in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.